110 related articles for article (PubMed ID: 7621566)
21. Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred.
Burgess JR; Shepherd JJ; Parameswaran V; Hoffman L; Greenaway TM
J Clin Endocrinol Metab; 1996 Jul; 81(7):2642-6. PubMed ID: 8675591
[TBL] [Abstract][Full Text] [Related]
22. An unusual kindred of the multiple endocrine neoplasia type 1 (MEN1) in Japanese.
Abe T; Yoshimoto K; Taniyama M; Hanakawa K; Izumiyama H; Itakura M; Matsumoto K
J Clin Endocrinol Metab; 2000 Mar; 85(3):1327-30. PubMed ID: 10720085
[No Abstract] [Full Text] [Related]
23. Sex differences in the development of prolactinoma in mice overexpressing hCGβ: role of TGFβ1.
Faraoni EY; Camilletti MA; Abeledo-Machado A; Ratner LD; De Fino F; Huhtaniemi I; Rulli SB; Díaz-Torga G
J Endocrinol; 2017 Mar; 232(3):535-546. PubMed ID: 28096433
[TBL] [Abstract][Full Text] [Related]
24. Mapping the gene for hereditary hyperparathyroidism and prolactinoma (MEN1Burin) to chromosome 11q: evidence for a founder effect in patients from Newfoundland.
Petty EM; Green JS; Marx SJ; Taggart RT; Farid N; Bale AE
Am J Hum Genet; 1994 Jun; 54(6):1060-6. PubMed ID: 7911003
[TBL] [Abstract][Full Text] [Related]
25. Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma.
Cavaco B; Leite V; Santos MA; Arranhado E; Sobrinho LG
J Clin Endocrinol Metab; 1995 Aug; 80(8):2342-6. PubMed ID: 7629227
[TBL] [Abstract][Full Text] [Related]
26. [Hyperprolactinemia].
Müller OA; von Werder K
Z Arztl Fortbild (Jena); 1991 Feb; 85(3-4):125-30. PubMed ID: 1676201
[No Abstract] [Full Text] [Related]
27. Surgery, dopamine agonist therapy of combined treatment--results in prolactinoma patients after a 12 month follow-up.
Hildebrandt G; Bauer T; Stracke H; Fassbender WJ; Mueller HW; Agnoli AL; Federlin K; Roosen K
Zentralbl Neurochir; 1992; 53(3):123-34. PubMed ID: 1414079
[TBL] [Abstract][Full Text] [Related]
28. Time Course of Resolution of Hyperprolactinemia After Transsphenoidal Surgery Among Patients Presenting with Pituitary Stalk Compression.
Zaidi HA; Cote DJ; Castlen JP; Burke WT; Liu YH; Smith TR; Laws ER
World Neurosurg; 2017 Jan; 97():2-7. PubMed ID: 27671881
[TBL] [Abstract][Full Text] [Related]
29. The soluble major histocompatibility complex class I-related chain A protein reduced NKG2D expression on natural killer and T cells from patients with prolactinoma and non-secreting pituitary adenoma.
Ma L; Li G; Su Y; He Q; Zhang C; Zhang J
J Clin Neurosci; 2010 Feb; 17(2):241-7. PubMed ID: 20045334
[TBL] [Abstract][Full Text] [Related]
30. Pituitary atypical teratoid rhabdoid tumor in a patient with prolactinoma: A unique description.
Barresi V; Lionti S; Raso A; Esposito F; Cannavò S; Angileri FF
Neuropathology; 2018 Jun; 38(3):260-267. PubMed ID: 29110337
[TBL] [Abstract][Full Text] [Related]
31. High prolactin level.
Piketty ML; Nataf F; Dilouya A; Roux FX
J Neurosurg; 2000 Feb; 92(2):368-9. PubMed ID: 10659034
[No Abstract] [Full Text] [Related]
32. Serum prolactin bioactivity and immunoactivity in hyperprolactinaemic states.
Smith CR; Butler J; Hashim I; Norman MR
Ann Clin Biochem; 1990 Jan; 27 ( Pt 1)():3-8. PubMed ID: 2310154
[TBL] [Abstract][Full Text] [Related]
33. The characteristics of acromegalic patients with hyperprolactinemia and the differences with hyperprolactinemia patients.
Huan C; Cui G; Ren Z
Pak J Pharm Sci; 2015 Mar; 28(2 Suppl):713-8. PubMed ID: 25796163
[TBL] [Abstract][Full Text] [Related]
34. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
35. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
Hu J; Zheng X; Zhang W; Yang H
Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
[TBL] [Abstract][Full Text] [Related]
36. A predictive algorithm for evaluating elevated serum prolactin in patients with a sellar mass.
Cheng JS; Salinas R; Molinaro A; Chang EF; Kunwar S; Blevins L; Aghi MK
J Clin Neurosci; 2015 Jan; 22(1):155-60. PubMed ID: 25481269
[TBL] [Abstract][Full Text] [Related]
37. Prolactinoma and body weight: a retrospective study.
Creemers LB; Zelissen PM; van 't Verlaat JW; Koppeschaar HP
Acta Endocrinol (Copenh); 1991 Oct; 125(4):392-6. PubMed ID: 1957557
[TBL] [Abstract][Full Text] [Related]
38. The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders.
Kostrzak A; Warenik-Szymankiewicz A; Meczekalski B
Gynecol Endocrinol; 2009 Dec; 25(12):799-806. PubMed ID: 19905999
[TBL] [Abstract][Full Text] [Related]
39. Somatotrophinomas in multiple endocrine neoplasia type 1: a review of clinical phenotype and insulin-like growth factor-1 levels in a large multiple endocrine neoplasia type 1 kindred.
Burgess JR; Shepherd JJ; Parameswaran V; Hoffman L; Greenaway TM
Am J Med; 1996 May; 100(5):544-7. PubMed ID: 8644767
[TBL] [Abstract][Full Text] [Related]
40. The importance of macroprolactinemia in the differential diagnosis of hyperprolactinemic patients.
Bağdatoğlu C; Bağdatoğlu OT; Muslu N; Köseoğlu A; Dağtekin A; Polat G; Dolgun H; Karataş MA
Turk Neurosurg; 2008 Jul; 18(3):223-7. PubMed ID: 18814107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
